(Boursier.com) — Median Technologies announces significant new results regarding the ability of its iBiopsy Lung Cancer Screening (LCS) CADe/CADx medical device software, based on Artificial Intelligence and Machine Learning technologies, to characterize malignant lung nodules in low-dose CT images .
The new results show a considerable increase in the performance of Median’s proprietary algorithms, with a sensitivity of 96.5% for a specificity of 97.2% relating to the whole detection plus characterization of malignant pulmonary nodules. These new results are calculated on a cohort of 9,863 patients, representing 195,943 nodules (16,789 nodules for the results of March 22, 2022). As was the case previously, these performances correspond to the combination of detection and characterization at the level of all the pulmonary nodules.
The results will be presented at the European Congress of Radiology (ECR) at the AIX Theater on Wednesday March 1 (4:00 p.m. CET) and Thursday March 2 (1:30 p.m. CET).
Remember that the ECR is organized annually by the ESR (European Society of Radiology). It is the most important radiology congress in Europe and the second in the world. Every year, it brings together more than 20,000 participants, including more than 10,000 representatives of the medical community and more than 8,000 industrial participants (imaging modalities, PACS, etc.). Radiology professionals at European and global level attend training sessions there, discover the latest innovations presented by industrial exhibitors as well as research results during scientific presentations.
©2023 Boursier.com